Wednesday, July 8, 2026

pharma · Acute Myeloid Leukemias · Breast Cancer

Syndax Pharmaceuticals

Syndax Pharmaceuticals clinical programs — 16 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

730 3rd Ave, Floor 9, New York, NY 10017, US HQ
325 Employees
NMPA registrant Type
Company details
Status
Public
HQ
730 3rd Ave, Floor 9, New York, NY 10017, US
Employees
325
Programs
47
Drugs
29
Patents
6
Intelligence · Clinical Programs

Syndax Pharmaceuticals projects

16 ClinicalTrials.gov programs sponsored by Syndax Pharmaceuticals.

Syndax Pharmaceuticals has 16 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Axatilimab

    Syndax Pharmaceuticals

    Solid Tumor

    phase 1 small molecule completed

    1 trial
  2. Entinostat

    Syndax Pharmaceuticals

    Drug Interaction

    phase 1 small molecule completed

    1 trial
  3. Entinostat

    Syndax Pharmaceuticals

    Fallopian Tube Cancer

    phase 1 small molecule terminated

    1 trial
  4. Entinostat

    Syndax Pharmaceuticals

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial
  5. Entinostat

    Syndax Pharmaceuticals

    Neoplasms

    phase 1 small molecule completed

    2 trials
  6. Entinostat

    Syndax Pharmaceuticals

    Pancreas Cancer

    phase 1 small molecule terminated

    1 trial
  7. Entinostat

    Syndax Pharmaceuticals

    Renal Impairment

    phase 1 small molecule completed

    1 trial
  8. Entinostat

    Syndax Pharmaceuticals

    Volunteers

    phase 1 small molecule completed

    2 trials
  9. Revumenib

    Syndax Pharmaceuticals

    Acute Leukemia

    phase 1 small molecule completed

    1 trial
  10. Revumenib

    Syndax Pharmaceuticals

    Blinatumomab

    phase 1 small molecule active

    1 trial
  11. Revumenib

    Syndax Pharmaceuticals

    Refractory Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial
  12. Revumenib

    Syndax Pharmaceuticals

    Relapsed/Refractory Leukemias

    phase 1 small molecule completed

    1 trial
  13. SNDX-275

    Syndax Pharmaceuticals

    Breast Cancer

    phase 1 small molecule terminated

    1 trial
  14. SNDX-5613

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 1 small molecule active

    1 trial
  15. SNDX-5613-0708

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 1 other active

    1 trial
  16. entinostat

    Syndax Pharmaceuticals

    Lung Cancer

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Syndax Pharmaceuticals have?

16 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.